TFX Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of 14.52% compared to Teleflex's net margin of 8.28%. Teleflex's return on equity of 5.32% beat Globus Medical's return on equity of 2.27%.

Teleflex has a consensus price target of $240.93, signalling upside risk potential of 33.3%. On the other hand Globus Medical has an analysts' consensus of $93.85 which suggests that it could grow by 15.15%. Given that Teleflex has higher upside potential than Globus Medical, analysts believe Teleflex is more attractive than Globus Medical.

Teleflex has a beta of 1.157, which suggesting that the stock is 15.72% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.188, suggesting its more volatile than the S&P 500 by 18.849%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 0.76%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 17.93% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $764.4M, which are larger than Globus Medical quarterly revenues of $625.7M. Teleflex's net income of $111M is higher than Globus Medical's net income of $51.8M. Notably, Teleflex's price-to-earnings ratio is 35.60x while Globus Medical's PE ratio is 122.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.80x versus 4.53x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Haemonetics has a net margin of 14.52% compared to Teleflex's net margin of 9.79%. Teleflex's return on equity of 5.32% beat Haemonetics's return on equity of 13.51%.

Teleflex has a consensus price target of $240.93, signalling upside risk potential of 33.3%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 41.33%. Given that Haemonetics has higher upside potential than Teleflex, analysts believe Haemonetics is more attractive than Teleflex.

Teleflex has a beta of 1.157, which suggesting that the stock is 15.72% more volatile than S&P 500. In comparison Haemonetics has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.02%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 0.76%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 17.93% of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $764.4M, which are larger than Haemonetics quarterly revenues of $345.5M. Teleflex's net income of $111M is higher than Haemonetics's net income of $33.8M. Notably, Teleflex's price-to-earnings ratio is 35.60x while Haemonetics's PE ratio is 32.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.80x versus 2.96x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

PROCEPT BioRobotics has a net margin of 14.52% compared to Teleflex's net margin of -35.93%. Teleflex's return on equity of 5.32% beat PROCEPT BioRobotics's return on equity of -37.42%.

Teleflex has a consensus price target of $240.93, signalling upside risk potential of 33.3%. On the other hand PROCEPT BioRobotics has an analysts' consensus of $102.75 which suggests that it could grow by 23.56%. Given that Teleflex has higher upside potential than PROCEPT BioRobotics, analysts believe Teleflex is more attractive than PROCEPT BioRobotics.

Teleflex has a beta of 1.157, which suggesting that the stock is 15.72% more volatile than S&P 500. In comparison PROCEPT BioRobotics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 0.76%. PROCEPT BioRobotics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 17.93% of its earnings as a dividend. PROCEPT BioRobotics pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $764.4M, which are larger than PROCEPT BioRobotics quarterly revenues of $58.4M. Teleflex's net income of $111M is higher than PROCEPT BioRobotics's net income of -$21M. Notably, Teleflex's price-to-earnings ratio is 35.60x while PROCEPT BioRobotics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.80x versus 21.35x for PROCEPT BioRobotics. Usually stocks with elevated PS ratios are considered overvalued.

QuidelOrtho has a net margin of 14.52% compared to Teleflex's net margin of -2.74%. Teleflex's return on equity of 5.32% beat QuidelOrtho's return on equity of -47.52%.

Teleflex has a consensus price target of $240.93, signalling upside risk potential of 33.3%. On the other hand QuidelOrtho has an analysts' consensus of $50.29 which suggests that it could grow by 13.55%. Given that Teleflex has higher upside potential than QuidelOrtho, analysts believe Teleflex is more attractive than QuidelOrtho.

Teleflex has a beta of 1.157, which suggesting that the stock is 15.72% more volatile than S&P 500. In comparison QuidelOrtho has a beta of 0.079, suggesting its less volatile than the S&P 500 by 92.104%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 0.76%. QuidelOrtho offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 17.93% of its earnings as a dividend. QuidelOrtho pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $764.4M, which are larger than QuidelOrtho quarterly revenues of $727.1M. Teleflex's net income of $111M is higher than QuidelOrtho's net income of -$19.9M. Notably, Teleflex's price-to-earnings ratio is 35.60x while QuidelOrtho's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.80x versus 1.07x for QuidelOrtho. Usually stocks with elevated PS ratios are considered overvalued.